Rossari Biotech ‘s Q3 2024-25 Latest News: Profit Drops by 7.82% YoY

Today, we’re looking at Rossari Biotech Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 10.56 %. However, it did see a marginal increase of 2.89 % from the previous quarter. Expenses ticked up slightly by 3.6 % quarter-on-quarter, aligning with the annual rise of 11.96 %. Operating profit, while up 1.71 % compared to last year, faced a quarter-on-quarter dip of -1.79 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -1.1 %, but a shrinkage of -0.6 % sequentially. Other income fell by -23.37 % compared to the last quarter, despite an annual decline of -84.27 %. Interest expenses surged remarkably by 34.24 % from the previous quarter, yet the year-over-year increase remains at a moderate 14.35 %. Depreciation costs climbed by 20.84 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 21.4 %. Profit before tax declined annually by -11.96 % but saw a reduction from the preceding quarter by -12.07 %.
Tax expenses as a percentage of profits decreased slightly by -2.64 % compared to last year, with a more notable quarter-on-quarter decrease of -1.32 %. Net profit fell by -7.82 % year-on-year but witnessed a -10.27 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -7.89 % but a quarterly fall of -10.34 %. In summary, Rossari Biotech Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Rossari Biotech Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 10.56 % year-on-year growth, however, there was a minor increase of 2.89 % from the previous quarter. Expenses rose by 11.96 % compared to the previous year, with a 3.6 % increase quarter-on-quarter. Operating Profit surged by 1.71 % annually, and saw a -1.79 % decrease from the last quarter.
Net Profit showed yearly decrease of -7.82 %, and experienced a -10.27 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -7.89 % annually, however dipped by -10.34 % compared to the last quarter. In essence, while Rossari Biotech Limited faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.